Unlocking the Enigma: A Comprehensive Exploration of Allylescaline - The Lesser-Known Psychedelic

Table of Contents

  1. Summary
  2. Chemistry
    1. Chemical Properties
  3. Pharmacology
  4. Conclusion
  5. FAQ


4-Allyloxy-3,5-dimethoxyphenethylamine, commonly known as allylescaline, is a less-known psychedelic substance belonging to the phenethylamine class. Structurally, it is an analog of mescaline and shares similarities with escaline and methallylescaline. Despite its infrequent occurrence, allylescaline has little documented history of human usage. Alexander Shulgin detailed its effects in his book PiHKAL: A Chemical Love Story, citing an oral dosage range of 20-35 mg and a duration of action lasting 8-12 hours.

Chemistry

Allylescaline, with the chemical name 4-allyloxy-3,5-dimethoxyphenethylamine, is a substituted phenethylamine. It features a phenyl ring connected to an amino -NH2 group through an ethyl chain. The phenyl ring has two methoxy functional groups (CH3O-) attached to carbons R3 and R5, along with an additional allyloxy group at carbon R4. Essentially, allylescaline is the 4-allyloxy analog of mescaline.

Chemical Properties

  • IUPAC Name: 4-Allyloxy-3,5-dimethoxyphenethylamine
  • Molecular Formula: C13H19NO3
  • Molecular Weight: 237.29 g/mol
  • Average Mass: 237.294998 Da
  • Monoisotopic Mass: 237.136002 Da

Pharmacology

Allylescaline functions as a 5-HT2A partial agonist, suggesting that its psychedelic effects stem from its activity at the 5-HT2A receptors. Despite this understanding, the exact mechanisms leading to the psychedelic experience remain unclear.

It serves as the 4O-allyl homolog of mescaline, binding to serotonin receptors similarly. Notably, allylescaline exhibits increased potency by weight compared to mescaline, with reported active doses in humans ranging from 20-40 mg, as opposed to 300-400 mg for mescaline.

The scarcity of documented human usage and limited available data contribute to the ambiguity surrounding allylescaline's pharmacological properties, metabolism, and toxicity. Alexander Shulgin's observations in PiHKAL: A Chemical Love Story remain one of the primary sources detailing the effects of this compound.

In conclusion, allylescaline, with its structural resemblance to mescaline, presents intriguing pharmacological aspects that warrant further exploration and research.

Conclusion

In the realm of psychedelic compounds, 4-Allyloxy-3,5-dimethoxyphenethylamine, or allylescaline, emerges as a fascinating yet elusive substance. This exploration has delved into its chemical composition, pharmacological properties, and limited documented history of human usage.

While allylescaline shares structural analogs with mescaline, its 5-HT2A partial agonist activity and increased potency by weight raise intriguing questions about its psychedelic effects. The scarcity of data surrounding its pharmacology, metabolism, and toxicity emphasizes the need for further research to fully understand this compound.

Alexander Shulgin's descriptions in PiHKAL: A Chemical Love Story provide a valuable glimpse into the effects of allylescaline, but the journey to unravel its mysteries is far from complete. As scientific curiosity continues, allylescaline stands as a promising subject for exploration in the ever-evolving landscape of psychedelic research.

FAQ

Q1: What is the recommended dosage for allylescaline?

  • A: The recommended dosage, as outlined by Alexander Shulgin, ranges from 20-35 mg when taken orally.

Q2: How long does the effect of allylescaline last?

  • A: The duration of action for allylescaline is reported to be 8-12 hours.

Q3: Is allylescaline commonly used by humans?

  • A: Allylescaline is relatively uncommon, with little to no documented history of widespread human usage.

Q4: What sets allylescaline apart from other psychedelics?

  • A: Allylescaline distinguishes itself as a 5-HT2A partial agonist, and it exhibits increased potency by weight compared to mescaline.

Q5: Are there known risks or toxicity associated with allylescaline?

  • A: Limited data exists regarding the toxicity of allylescaline, emphasizing the importance of further research to understand its safety profile.